Jefferies has initiated coverage on Solventum Corp (SOLV) with a Hold rating as of September 10, 2025. This rating marks the firm's first assessment of the company, reflecting its analysis of Solventum's business, industry dynamics, and growth prospects.
Headquartered in St. Paul, Minnesota, Solventum operates in the health care sector and employs 22,000 full-time staff. The company, which went public on March 26, 2024, offers a diverse range of products through its segments: MedSurg, Dental Solutions, and Health Information Systems. The MedSurg segment provides solutions such as negative pressure wound therapy and surgical supplies, while Dental Solutions offers orthodontic products. Health Information Systems focuses on software solutions for healthcare systems.
As of November 20, 2025, Solventum boasts a market capitalization of $13.4 billion, with a price-to-earnings ratio of 8.80 and earnings per share of 8.69. Upcoming earnings reports are anticipated on May 6, 2026, with an estimated EPS of $1.51 and revenue of $2.0 billion, and on August 5, 2026, with an estimated EPS of $1.67 and revenue of $2.1 billion.
Analyst ratings, such as Jefferies' Hold designation, provide insights based on research and financial modeling. However, these assessments are subject to change as new information emerges. Investors should consider a range of factors, including company fundamentals and industry trends, when evaluating investment opportunities.
The announcement highlights Jefferies' current view of Solventum, which follows a series of recent analyst actions. Notably, Morgan Stanley upgraded its rating to Overweight from Equal-Weight in July 2025, while Wells Fargo and Piper Sandler maintained their ratings in August 2025.
As the health care landscape evolves, Solventum's performance will be closely watched by analysts and investors alike.